Investor Relations

Company Information

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Form Description Filing date View
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
SC 13D

Filing by person(s) reporting owned shares of common stock in a public company >5%

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML

Data provided by Kaleidoscope.